Evidence mapPaperPMID 9686693Full record

ArticleDiabetic medicine : a journal of the British Diabetic Association1998

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

K G Alberti, P Z Zimmet

11 registry-linked trialsAbstract read
PubMed Publisher
In one paragraph

Article in Diabetic medicine : a journal of the British Diabetic Association, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 11 registered trials, which are not on this map. Cited by 4,374 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4,374citing papers in PubMed, 5 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05343767 nacompletedstarted 2018, after this paper: background citation

A Phase II, Randomized, Double Blind, Double Dummy, Active-Controlled Clinical Trial to Investigate the Efficacy and Safety of Low-Glu in Patients Newly Diagnosed With Type II Diabetes Mellitus

Ran2018Enrolled198Registered outcomes6Posted comparisons0ConditionsType2 Diabetes MellitusArmsMetformin, Natural Wellness Low-Glu high dose, Natural Wellness Low-Glu low dose
Open the trial in the graph
NCT00390585 phase4completednot on this mapstarted 2006, after this paper: background citation

Prospective, Randomized, Comparative Study to Evaluate the Effect of Iodixanol 320 Compared to Iomeprol 350 on Contrast Medium Induced Nephropathy in Patients With Impaired Renal Function Undergoing PCI

TypeinterventionalSponsorDeutsches Herzzentrum MuenchenRan2006 to 2008Enrolled324ConditionsRenal Insufficiency, Chronic, Angioplasty, Transluminal, Percutaneous Coronary, Coronary ArteriosclerosisArmsIodixanol 320, Iomeprol 350
NCT01168700 phase4unknown statusnot on this mapstarted 2009, after this paper: background citation

A prospective, randomized, double-blind, placebo-controlled trial of the supplementation with kiolic® in patients with diagnosis of metabolic syndrome to improve endothelial function and inflammatory state. "kymes"

TypeinterventionalSponsorUniversidad de SantanderRan2009 to 2010Enrolled46ConditionsMetabolic SyndromeArmsaged garlic extract, Placebo
NCT02028091 completednot on this mapstarted 2012, after this paper: background citation

Diabetes Mellitus - A Diagnosis Trial by Means of Non Invasive Measurements

TypeobservationalSponsorMedical University of ViennaRan2012 to 2013Enrolled100ConditionsDiabetes Mellitus Type II
NCT03141398 withdrawnnot on this mapstarted 2017, after this paper: background citation

Continuous Glucose Monitoring (CGM) Versus Oral Glucose Tolerance Test (OGTT) Versus T2* MRI Of The Pancreas In High-Risk Group (Hemoglobinopathies, Lymphoma & Acute Lymphoblastic Leukemia): A Comparative Study

TypeobservationalSponsorHamad Medical CorporationRan2017 to 2018Enrolled0ConditionsIron Overload, Hemoglobinopathies, Lymphoma, Acute Lymphoblastic LeukemiaArmsContinuous Glucose Monitoring (CGM), Oral Glucose Tolerance Test (OGTT), T2* MRI of the Pancreas
NCT03898076 completednot on this mapstarted 2020, after this paper: background citation

The Prediction of A1c Based on CGM Data Through Applying Machine Learning Approaches

TypeobservationalSponsorSidra MedicineRan2020 to 2020Enrolled60ConditionsDiabetes Mellitus, Type 1ArmsFlash Glucose Monitoring, A1c, Predictive A1c
NCT04097483 nacompletednot on this mapstarted 2017, after this paper: background citation

The TELE-DD Project: a Nurse-led Randomised Controlled Trial on Treatment Adherence in Patients With Type 2 Diabetes and Comorbid Depression

TypeinterventionalSponsorAlicia Monreal BartoloméRan2017 to 2020Enrolled428ConditionsDiabetes Mellitus, Type 2, DepressionArmsTelephone Intervention Group
NCT04489966 nacompletednot on this mapstarted 2018, after this paper: background citation

Effects of Aerobic Training on Pancreatic Fat and Cognitive Function in Patients With Type 2 Diabetes

TypeinterventionalSponsorNanjing University of Traditional Chinese MedicineRan2018 to 2020Enrolled106ConditionsType 2 Diabetes MellitusArmsAerobic training
NCT05407207 narecruitingnot on this mapstarted 2018, after this paper: background citation

Therapeutic Plantar Electrical Stimulation Intervention During Hemodialysis to Improve Balance and Mobility

TypeinterventionalSponsorHamad Medical CorporationRan2018 to 2022Enrolled100ConditionsDiabetes Mellitus, Hemodialysis Complication, Cardiovascular Complication, Quality of LifeArmsTennant Biomodulator ®
NCT05935904 unknown statusnot on this mapstarted 2023, after this paper: background citation

The Progression of Metabolic Syndrome Components During Pregnancy, and the Risks for Adverse Pregnancy Outcomes in Jimma Zone, Southwest Ethiopia: A Prospective Cohort Study.

Typeobservational_patient_registrySponsorUniversity GhentRan2023 to 2024Enrolled526ConditionsMetabolic Syndrome, Pregnant Women, Birth Outcomes, Dietary HabitsArmsExposure, Non exposure
NCT07194577 nacompletednot on this mapstarted 2023, after this paper: background citation

"Effect of Moringa Oleifera Dehydrated Leaf Powder on the Components of Metabolic Syndrome in Mexican Adults. Double-blind Randomized Clinical Trial. Phase II"

TypeinterventionalSponsorUniversidad de ColimaRan2023 to 2024Enrolled36ConditionsNutritional and Metabolic Diseases, Metabolic SyndromeArmsMoringa oleifera, Placebo
3 · Its place in the literature

Who cites it

4,374 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. World journal of diabetes · 2025
    Trial
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

4,314 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

K G AlbertiDepartment of Medicine, University of Newcastle upon Tyne, UK.
P Z Zimmet

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The classification of diabetes mellitus and the tests used for its diagnosis were brought into order by the National Diabetes Data Group of the USA and the second World Health Organization Expert Committee on Diabetes Mellitus in 1979 and 1980. Apart from minor modifications by WHO in 1985, little has been changed since that time. There is however considerable new knowledge regarding the aetiology of different forms of diabetes as well as more information on the predictive value of different blood glucose values for the complications of diabetes. A WHO Consultation has therefore taken place in parallel with a report by an American Diabetes Association Expert Committee to re-examine diagnostic criteria and classification. The present document includes the conclusions of the former and is intended for wide distribution and discussion before final proposals are submitted to WHO for approval. The main changes proposed are as follows. The diagnostic fasting plasma (blood) glucose value has been lowered to > or =7.0 mmol l(-1) (6.1 mmol l(-1)). Impaired Glucose Tolerance (IGT) is changed to allow for the new fasting level. A new category of Impaired Fasting Glycaemia (IFG) is proposed to encompass values which are above normal but below the diagnostic cut-off for diabetes (plasma > or =6.1 to <7.0 mmol l(-1); whole blood > or =5.6 to <6.1 mmol l(-1)). Gestational Diabetes Mellitus (GDM) now includes gestational impaired glucose tolerance as well as the previous GDM. The classification defines both process and stage of the disease. The processes include Type 1, autoimmune and non-autoimmune, with beta-cell destruction; Type 2 with varying degrees of insulin resistance and insulin hyposecretion; Gestational Diabetes Mellitus; and Other Types where the cause is known (e.g. MODY, endocrinopathies). It is anticipated that this group will expand as causes of Type 2 become known. Stages range from normoglycaemia to insulin required for survival. It is hoped that the new classification will allow better classification of individuals and lead to fewer therapeutic misjudgements.

Indexed as

World Health OrganizationAutoimmune DiseasesBlood GlucoseDiabetes, GestationalDiabetes MellitusFastingFemaleGlucose IntoleranceGlucose Tolerance TestHumansInsulin ResistanceIslets of LangerhansMutationPregnancyReference ValuesBlood Glucose

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

and 5 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.